Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$276.80 USD

276.80
530,933

-7.80 (-2.74%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $276.78 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong buoyed by Cologuard volume growth.

Zacks Equity Research

Omnicell (OMCL) Progresses With Intelligent Infrastructure Tools

by Zacks Equity Research

Omnicell's (OMCL) IVX Station robotic compounding technology apparently supports three times the throughput speed of the current IV robotic technology.

Zacks Equity Research

Edwards Lifesciences (EW) Up 7.5% Since Q4 Earnings Release

by Zacks Equity Research

Edwards Lifesciences' (EW) stock rallies on impressive fourth-quarter performance and bullish 2022 guidance.

Zacks Equity Research

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on the growing market adoption of the iTero Element 5D Plus imaging system.

Zacks Equity Research

Alcon (ALC) Publishes Dividend, New Board Member Addition Plans

by Zacks Equity Research

Alcon's 2022 AGM is set to take place in a closed format without the personal presence of shareholders.

Zacks Equity Research

Medtronic (MDT) Completes 1st Patient Implant of Implantable TNM

by Zacks Equity Research

Medtronic's (MDT) TITAN 2 study will examine the safety and efficacy of the implantable TNM device in people with OAB.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN's (QGEN) recent expansion in test menu and strategic collaborations.

Zacks Equity Research

Neogen's (NEOG) Q3 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Robust segmental performance and contributions from the Soleris product line drive the top line for Neogen (NEOG) in third-quarter of fiscal 2022 results.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on its progress with COVID-19-related products and services.

Zacks Equity Research

QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing

by Zacks Equity Research

According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.

Zacks Equity Research

Henry Schein (HSIC) Stock Moves Up 16.9%: What's Driving It?

by Zacks Equity Research

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Zacks Equity Research

Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

by Zacks Equity Research

Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

Zacks Equity Research

Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails

by Zacks Equity Research

Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.

Zacks Equity Research

Myriad Genetics (MYGN) Makes Progress in Precision Oncology

by Zacks Equity Research

Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

Zacks Equity Research

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.

Zacks Equity Research

Walgreens (WBA), Village MD Plan to Expand Into New Hampshire

by Zacks Equity Research

Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.

Zacks Equity Research

Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Zacks Equity Research

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

by Zacks Equity Research

Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.

Zacks Equity Research

Here's Why You Should Hold Onto Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.

Zacks Equity Research

Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes

by Zacks Equity Research

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

Zacks Equity Research

STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays

by Zacks Equity Research

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Zacks Equity Research

Cardiovascular Systems (CSII) Finances New DCB Development

by Zacks Equity Research

Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.

Zacks Equity Research

Medtronic (MDT) Inks Deal to Offer Touch Surgery Enterprise

by Zacks Equity Research

Medtronic's (MDT) Touch Surgery Enterprise gives surgical teams a powerful new tool to enhance patient care by simplifying the process to capture and analyze surgical videos.

Zacks Equity Research

Bio-Rad (BIO) Loses 15.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Bio-Rad (BIO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.